Blackstone, Carlyle Lead $3 Billion Medline Secondary Offering
Event summary
- Medline's selling stockholders (Blackstone, Carlyle, Hellman & Friedman, and Abu Dhabi Investment Authority) priced a $3.075 billion secondary offering of 75 million Class A shares at $41 each.
- Underwriters have a 30-day option to purchase an additional 11.25 million shares, potentially raising the deal size to $3.51 billion.
- Medline itself is not selling shares and will not receive any proceeds from the offering.
- The offering is expected to close on March 10, 2026.
The big picture
This blockbuster secondary offering represents the largest single liquidity event for Medline's private equity backers since its 2021 IPO. The $3 billion+ deal underscores both the scale of institutional ownership in healthcare distribution and the strategic timing of PE firms capitalizing on strong market conditions. With no proceeds flowing to Medline itself, the transaction primarily serves as an exit mechanism for early investors rather than a growth financing event.
What we're watching
- Private Equity Exits
- How this $3 billion+ offering will impact Blackstone, Carlyle, and other PE firms' positions in Medline's governance.
- Market Valuation
- Whether the $41/share pricing reflects peak valuation or leaves room for further upside/downside.
- Operational Independence
- The pace at which Medline can demonstrate standalone performance metrics now that major PE backers are reducing stakes.